Obseva (NASDAQ:OBSV) posted its quarterly earnings data on Thursday. The company reported ($0.42) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.46) by $0.04, Morningstar.com reports.
OBSV traded down $0.57 on Friday, hitting $15.35. 26,596 shares of the company traded hands, compared to its average volume of 137,080. The company has a market cap of $584.80 million, a PE ratio of -6.82 and a beta of 1.75. Obseva has a 12-month low of $9.05 and a 12-month high of $20.35.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. VHCP Management II LLC raised its stake in Obseva by 5.1% during the 2nd quarter. VHCP Management II LLC now owns 2,252,460 shares of the company’s stock valued at $34,102,000 after acquiring an additional 108,617 shares during the last quarter. FMR LLC acquired a new position in Obseva during the 2nd quarter worth approximately $27,254,000. First Manhattan Co. increased its position in Obseva by 1.6% during the 3rd quarter. First Manhattan Co. now owns 1,532,466 shares of the company’s stock worth $27,630,000 after purchasing an additional 23,500 shares during the period. Vivo Capital LLC acquired a new position in Obseva during the 2nd quarter worth approximately $14,005,000. Finally, Acuta Capital Partners LLC acquired a new position in Obseva during the 2nd quarter worth approximately $6,424,000. 68.33% of the stock is owned by hedge funds and other institutional investors.
Obseva Company Profile
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Read More: Swap
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.